Discover key facts about the healthcare market in Germany and learn about our latest market research for our pharmaceutical, medical device, and healthcare sector clients.
Key facts about the German health market:
Funding in the German healthcare system
Germany has a statutory health insurance system, which provides inpatient, outpatient, mental health, and prescription drug coverage. The government has a limited role in the direct delivery of healthcare, with sickness funds (non-governmental insurers) handling administration.
Health technology assessment in the Germany
The federal government has wide-ranging regulatory power over healthcare, but is not directly involved in care delivery.
The Federal Joint Committee (G-BA), which is supervised by the Federal Ministry of Health, determines the medicinal products to be covered by sickness funds.
Coverage decisions are based on evidence from comparative-effectiveness reviews and health technology (benefit-risk) assessments.
Reimbursement of medical devices is dependent on inclusion in new or existing diagnosis-related group (DRG) codes. G-BA/the Institute for Quality and Efficiency in Health Care (IQWiG) will be requested to conduct an assessment before technologies are routinely reimbursed by statutory health insurance (SHI) funds. There are special pathways for digital applications involving the Federal Institute for Drugs and Medical Devices (BfArM).
Germany payers’ primary focus:
The German market is clinically focused first and foremost.
To discuss your German launch strategy with our experts or to enquire about market research services, get in touch using the form below.
Our work in the German market
At Mtech Access, we have a global network of Associates, including experts across Germany. Their insights inform our primary research and validate our secondary research.
Here are just a few examples of how we have supported clients looking to understand and influence the healthcare market in Germany:
View Case StudyExploring funding and reimbursement routes for digital health technologies across EU4, UK and US
View Case StudyModelling pricing and market dynamics in a competitive therapeutic landscape across the EU4 and UK markets
View Case StudyResearching market access pathways, reimbursement requirements and implications of orphan drug designation for a rare disease product
View Case StudyGaining global payer insights to inform clinical trial design, price and market access strategy
View Case StudyReviewing HTA decisions in key markets across the globe
View Case StudyChallenging European policy proposals with an evidence-driven submission on behalf of a cross-industry consortium
More German market insights and research
Market access in the German-speaking markets
In this webinar, we explore market access challenges in Germany, Austria, and Switzerland. Clare Foy (Director – Global Market Access, Mtech Access) speaks to Dr Stefan Walzer about the challenges and opportunities for reimbursement in the German-speaking markets.
EU Joint Clinical Assessment (JCA) – implications for Pharma and Medtech
Our health technology assessment experts provide an overview of the EU Joint Clinical Assessment (JCA) and what it means for Pharma and Medical Device manufacturers launching new technologies from 2025
Evolving market access pathways for AI-enabled Medtech in Europe
Louise Maddison (Senior Consultant – Global Market Access, Mtech Access) explores the evolving market access landscape for AI-enabled Medtech, with a particular focus on the key European markets of France, Germany and the UK.
